Gaucher Disease: Clinical, Biological and Therapeutic Aspects

Pathobiology

Volumn 83, Issue 1, 2016, Pages 13-23

  Dandana, Azza ^a   Ben Khelifa, Souhaira ^a   Chahed, Hinda ^a   Miled, Abdelhédi ^a   Ferchichi, Salima ^a  

^a FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

Gaucher disease; Lysosomal storage disease; Therapeutic aspect; Glucocerebrosidase

Indexed keywords

ALLELE; ANEMIA; DISEASE CLASSIFICATION; DNA POLYMORPHISM; ENZYME REPLACEMENT; GAUCHER DISEASE; GENE MUTATION; HEPATOSPLENOMEGALY; HUMAN; HYPERSPLENISM; INTERVENTION STUDY; MEDICAL HISTORY; NEUTROPENIA; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; TUNISIAN; GENE THERAPY; GENETICS; PATHOPHYSIOLOGY; SPLENOMEGALY;

GLUCOSYLCERAMIDASE;

ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; GENETIC THERAPY; GLUCOSYLCERAMIDASE; HUMANS; HYPERSPLENISM; SPLENOMEGALY;

EID: 84947812571     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000440865     Document Type: Review

References (90)

1. Wraith JE: The clinical presentation of lysosomal storage disorders. Acta Neurol Taiwan 2004; 13: 101-106.
2. Brady RO, Kanfer JN, Shapiro D: Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 1965; 18: 221-225.
3. Beutler E, Grabowski GA: Gaucher disease; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Basis of Inherited Disease, ed 8. New York, McGraw-Hill, 2001, vol III, pp 3635-3668.
4. Beutler E, Grabowski G: Glucosylceramidelipidoses: Gaucher disease; in Scriver CR, Beaudet AL, Sly WS (eds): The Metabolic and Molecular Bases of Inherited Diseases. New York, McGrew-Hill, 1995, pp 2641-2670.
5. Bieberich E, Freischutz B, Suzuki M, et al: Differential effects of glycolipid biosynthesis inhibitors on ceramide-induced cell death in neuroblastoma cells. J Neurochem 1999; 72: 1040-1049.
6. Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
7. Brinkman J, Wijburg FA, Hollak CE, et al: Plasma chitotriosidase and CCL18: early biochemical surrogate markers in type B Niemann-Pick disease. J Inherit Metab Dis 2005; 28: 13-20.
8. Boven LA, van Meurs M, Boot RG, et al: Gaucher cells demonstrae a distinct macrophage phenotype and resemble alternatively activated macrophages. Am Clin Pathol 2004; 122: 359-369.
9. Schroder M, Kaufman RJ: ER stress and the unfolded protein response. Mutat Res 2005; 569: 29-63.
10. Gargalovic PS, Gharavi NM, et al: The unfolded protein response is an important regulator of inflammatory genes in endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26: 2490-2496.
11. Tessitore A, del P Martin M, Sano R, et al: GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol Cell 2004; 15: 753-766.
12. Lloyd-Evans E, Pelled D, Riebeling C, et al: Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J Biol Chem 2003; 278: 23594-23599.
13. Korkotian E, Schwarz A, Pelled D, et al: Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J Biol Chem 1999; 274: 21673-21678.
14. Mikosch P: Gaucher disease and bone. Best Pract Res Clin Rheumatol 2011; 25: 665-681.
15. Pastores GM: Neuropathic Gaucher disease. Wien Med Wschr 2010; 160: 605-608.
16. Walton-Bowen K, Mantick N: Gaucher registry annual aggregate data report. 2000.
17. Mehta A: Epidemiology and natural history of Gaucher's disease. Eur J Intern Med 2006; 17:S2-S5.
18. Germain DP: Gaucher's disease: a paradigm for interventional genetics. Clin Genet 2004; 65: 77-86.
19. Cox TM: Gaucher disease: clinical profile and therapeutic developments. Biologics 2010; 4: 299-313.
20. Grabowski G: Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test 1997; 1: 5-12.
21. Beutler E, Nguyen NJ, Henneberger MW, et al: Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet 1993b;52: 85-88.
22. Grabowski GA, Horowitz M: Gaucher's disease: molecular, genetic and enzymological aspects. Baillieres Clin Haematol 1997; 10: 635-656.
23. Koprivica V, Stone DL, Park JK, et al: Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 2000; 66: 1777-1786.
24. Kathleen S, Hruska, Mary E, et al: Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA) . Hum Mutat 2008; 29: 567-583.
25. Eyal N, Firon N, Wilder S, et al: Three unique base pair changes in a family with Gaucher disease. Hum Genet 1991; 87: 328-332.
26. Hong CM, Ohashi T, Yu XJ, et al: Sequence of two alleles responsible for Gaucher disease. DNA Cell Biol 1990; 9: 233-241.
27. Latham T, Grabowski GA, Theophilus BD, et al: Complex alleles of the acid beta-glucosidase gene in Gaucher disease. Am J Hum Genet 1990; 47: 79-86.
28. Latham TE, Theophilus BD, Grabowski GA, et al: Heterogeneity of mutations in the acid beta-glucosidase gene of Gaucher disease patients. DNA Cell Biol 1991; 10: 15-21.
29. Tayebi N, Stubblefield BK, Park JK, et al: Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease. Am J Hum Genet 2003; 72: 519-534.
30. Zimran A, Sorge J, Gross E, et al: A glucocerebrosidase fusion gene in Gaucher disease: implications for the molecular anatomy, pathogenesis, and diagnosis of this disorder. J Clin Invest 1990b;85: 219-222.
31. Sarria AJ, Giraldo P, Perez-Calvo JI, et al: Detection of three rare (G377S, T134P and 1451delAC), and two novel mutations (G195W and Rec[1263del55; 1342G>C]) in Spanish Gaucher disease patients. Mutation in Brief No. 251. Hum Mutat 1999; 14: 88.
32. Cormand B, Diaz A, Grinberg D, et al: A new genepseudogene fusion allele due to a recombination in intron 2 of the glucocerebrosidase gene causes Gaucher disease. Blood Cells Mol Dis 2000; 26: 409-416.
33. Stone DL, Tayebi N, Orvisky E, et al: Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat 2000b;15: 181-188.
34. Beutler E, Demina A, Gelbart T: Glucocerebrosidase mutations in Gaucher disease. Mol Med 1994; 1: 82-92.
35. Park JK, Tayebi N, Stubblefield BK, et al: The E326K mutation and Gaucher disease: mutation or polymorphism? Clin Genet 2002; 61: 32-34.
36. Walker JM, Lwin A, Tayebi N, et al: Glucocerebrosidase mutation T369M appears to be another polymorphism. Clin Genet 2003; 63: 237-238.
37. Torralba MA, Perez-Calvo JI, Pastores GM, et al: Erratum: identification and characterization of a novel mutation c.1090G4T (G325W) and nine common mutant alleles leading to Gaucher disease in Spanish patients. Blood Cells Mol Dis 2001a;27: 713.
38. Torralba MA, Perez-Calvo JI, Pastores GM, et al: Identification and characterization of a novel mutation c.1090G4T (G325W) and nine common mutant alleles leading to Gaucher disease in Spanish patients. Blood Cells Mol Dis 2001b;27: 489-495.
39. Hruska K, LaMarca ME, Sidransky E: Gaucher disease: molecular biology and genotype-phenotype correlations; in Futerman AH, Zimran A (eds): Gaucher Disease. Boca Raton, CRC Press, 2007; pp 13-48.
40. Sorge J, Gelbart T, West C, et al: Heterogeneity in type I Gaucher disease demonstrated by restriction mapping of the gene. Proc Natl Acad Sci USA 1985a;82: 5442-5445.
41. Zimran A, Gelbart T, Beutler E: Linkage of the PvuII polymorphism with the common Jewish mutation for Gaucher disease. Am J Hum Genet 1990a;46: 902-905.
42. Beutler E, West C, Gelbart T: Polymorphisms in the human glucocerebrosidase gene. Genomics 1992b;12: 795-800.
43. Amaral O, Marcao A, Pinto E, et al: Distinct haplotype in non-Ashkenazi Gaucher patients with N370S mutation. Blood Cells Mol Dis 1997; 23: 415-416.
44. Cormand B, Grinberg D, Gort L, et al: Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. Hum Mutat 1998a;11: 295-305.
45. Demina A, Beutler E: Six new Gaucher disease mutations. Acta Haematol 1998; 99: 80-82.
46. Lacerda L, Amaral O, Pinto R, et al: The N370S mutation in the glucocerebrosidase gene of Portuguese type 1 Gaucher patients: linkage to the PvuII polymorphism. J Inherit Metab Dis 1994; 17: 85-88.
47. Rockah R, Narinsky R, Frydman M, et al: Linkage disequilibrium of common Gaucher disease mutations with a polymorphic site in the pyruvate kinase (PKLR) gene. Am J Med Genet 1998; 78: 233-236.
48. Rodriguez-Mari A, Diaz-Font A, Chabas A, et al: New insights into the origin of the Gaucher disease causing mutation N370S: extended haplotype analysis using the 5GC3.2, 5470 G/A, and ITG6.2 polymorphisms. Blood Cells Mol Dis 2001; 27: 950-959.
49. Lau EK, Tayebi N, Ingraham LJ, et al: Two novel polymorphic sequences in the glucocerebrosidase gene region enhance mutational screening and founder effect studies of patients with Gaucher disease. Hum Genet 1999; 104: 293-300.
50. Sidransky E, Nalls MA, Aasly JO, et al: Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361: 1651-1661.
51. de Rijk MC, Launer LJ, Berger K, et al: Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54(11 suppl 5):S21-S23.
52. Bekris LM, Mata IF, Zabetian CP: The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010; 23: 228-242.
53. Zimran A, Neudorfer O, Elstein D: The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2005; 352: 728-731.
54. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R: Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2004; 351: 1972-1977.
55. Goker-Alpan O, Schiffmann R, LaMarca ME, et al: Parkinsonism among Gaucher disease carriers. J Med Genet 2004; 41: 937-940.
56. Halperin A, Elstein D, Zimran A: Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cell Mol Dis 2006; 6: 426-428.
57. Mitsui J, Mizuta I, Toyoda A, et al: Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 2009; 66: 571-576.
58. Lesage S, Anheim M, Condroyer C, et al: Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet 2011; 20: 202-210.
59. Kamath RS, Lukina E, Watman N, et al: Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol 2014; 43: 1353-1360.
60. Rosenthal DI, Scott JA, Barranger J, et al: Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg Am 1986; 68: 802-808.
61. Mistry PK, Weinreb NJ, Kaplan P, et al: Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis 2011; 46: 66-72.
62. Maas M, Poll LW, Terk MR: Imaging and quantifying skeletal involvement in Gaucher disease. Br J Radiol 2002; 75(suppl 1):A13-A24.
63. Kuter DJ, Mehta A, Hollak CEM, et al: Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis 2013; 51: 116-124.
64. Elstein D, Hollak C, Aerts JM, et al: Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004; 27: 757-766.
65. Heitner R, Elstein D, Aerts J, et al: Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 2002; 28: 127-133.
66. Pastores GM, Giraldo P, Cherin P, et al: Goaloriented therapy with miglustat in Gaucher disease. Curr Med Res Opin 2009; 25: 23-37.
67. Elstein D, Dweck A, Attias D, et al: Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch fromor combination with intravenous enzyme replacement. Blood 2007; 110: 2296-2301.
68. Pastores GM, Elstein D, Hrebicek M, et al: Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther 2007; 29: 1645-1654.
69. Martinez-Arias R, Calafell F, Mateu E, et al: Sequence variability of a human pseudogene. Genome Res 2001a;11: 1071-1085.
70. Zimran A: How I treat Gaucher disease. Blood 2011; 118: 6.
71. Barton NW, Brady RO, Dambrosia JM, et al: Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324: 1464-1470.
72. Lukina E, Watman N, Arreguin EA, et al: Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 2010; 116: 4095-4098.
73. Deegan PB, Cox TM: Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther 2012; 6: 81-106.
74. Horowitz M, Wilder S, Horowitz Z, et al: The human glucocerebrosidase gene and pseudogene: structure and evolution. Genomics 1989; 4: 87-96.
75. Ron I, Horowitz M: ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 2005; 14: 2387-2398.
76. Kornhaber GJ, Tropak MB, Maegawa GH, et al: Isofagomine induced stabilization of glucocerebrosidase. Chem Biochem 2008; 9: 2643-2649.
77. Maegawa GH, Tropak MB, Buttner JD, et al: Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 2009; 284: 23502-23516.
78. Laoag-Fernandez JB, Fernandez AM, Maruo T: Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome. J Obstet Gynaecol Res 2000; 26: 307-312.
79. Peters C, Krivit W: Hematopoietic stem cell therapy, stem cells and gene therapy; in Futerman AH, Zimran A (eds): Gaucher Disease. Boca Raton, CRC Press, 2007, pp 423-438.
80. Enquist IB, Nilsson E, Mansson JE, et al: Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease. Stem Cells 2009; 27: 744-752.
81. Grabowski GA: Gaucher disease and other storage disorders. Hematol Am Soc Hematol Educ Program 2012; 1: 13-18.
82. Brautbar A, Abrahamov A, Hadas-Halpern I, et al: Gaucher disease in Arab patients at an Israeli referral clinic. Isr Med Assoc J 2008; 10: 600-602.
83. Chaabouni M, Aoulou H, Tebib N, et al: Gaucher's disease in Tunisia (multicenter study). Rev Med Interne 2004; 25: 104-110.
84. Cherif W, Ben Turkia H, Ben Rhouma F, et al: Gaucher disease in Tunisia: high frequency of the most common mutations. Blood Cells Mol Dis 2009; 43: 161-162.
85. Alfonso P, Cenarro A, Perez-Calvo JI, et al: Mutation prevalence among 51 unrelated Spanish patients with Gaucher disease: identification of 11 novel mutations. Blood Cells Mol Dis 2001; 27: 882-891.
86. Filocamo M, Mazzotti R, Stroppiano M, et al: Analysis of the glucocerebrosidase gene and mutation profile in 144 Italian Gaucher patients. Hum Mutat 2002; 20: 234-235.
87. Rodriguez-Mari A, Diaz-Font A, Chabas A, et al: New insights into the origin of the Gaucher disease-causing mutation N370S: extended haplotype analysis using the 5GC3.2, 5470 G/A, and ITG6.2 polymorphisms. Blood Cells Mol Dis 2001; 27: 950-959.
88. Ben Turkia H, Riahi I, Azzouz H, Ladab S, et al: Phenotype and mutational spectrum in Tunisian pediatric Gaucher disease. Tunis Med 2010; 88: 158-162.
89. Ben Rhouma F, Kallel F, Kefi R, et al: Adult Gaucher disease in southern Tunisia: report of three cases. Diagn Pathol 2012; 7: 4.
90. Dandana A, Ferchichi S, Khedhiri S, et al: Biochemical and molecular diagnosis of Gaucher disease in Tunisia. Ann Biol Clin (Paris) 2007; 65: 647-652.